Palbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry

Simple item page
dc.catalogadorjlo
dc.contributor.authorWalbaum García, Benjamín Vicente
dc.contributor.authorReyes, José Miguel
dc.contributor.authorRodríguez, Pablo
dc.contributor.authorMuñiz Muñoz, María Sabrina
dc.contributor.authorMedina Araya, Lidia Marjorie
dc.contributor.authorIbáñez Cáceres, Carolina
dc.contributor.authorMerino Lara, Tomás Rodrigo
dc.contributor.authorPinto, Mauricio
dc.contributor.authorBravo, María Loreto
dc.contributor.authorAcevedo Claros, Francisco Nicolás
dc.contributor.authorBennett Laso, José Tomás
dc.contributor.authorSánchez Rojel, César Giovanni
dc.date.accessioned2024-03-27T13:32:02Z
dc.date.available2024-03-27T13:32:02Z
dc.date.issued2023
dc.description.abstractBackground The addition of cyclin-dependent kinases inhibitors (CDKi) to endocrine therapy (ET) as the first- or second line treatment improves progression-free and overall survival (OS) in hormone receptor-positive, HER2 negative (HR+/HER2-) advanced stage breast cancer (ABC). Our study compared survival rates and prognostic factors in Chilean patients that used palbociclib as first or subsequent (≥second) lines of treatment in a real-world setting.Methods Our retrospective population-cohort study included HR+/HER2- ABC patients. We calculated 5-year OS and performed a multivariate analysis to determine prognostic factors.Results A total of 106 patients were included. Median age was 49 years (19–86), 28.3% (30) had de novo stage IV disease; 63% received palbociclib with ET as first line, 54% of them with aromatase inhibitor over fulvestrant. Median OS for the entire cohort was 99 months and 5-year OS was 69%. Patients that received first line palbociclib had a 5-year OS of 89% versus 43% for ET monotherapy or ≥second line palbociclib (p = 0.0062). Multivariate analysis showed that the year at diagnosis and CDKi timing (first line versus ≥second line) were significantly associated with OS.Conclusion Our real-world data show that first-line CDKi + ET provides a statistically significant benefit in OS versus ≥second line in HR+/HER2- ABC patients.
dc.fechaingreso.objetodigital2024-04-02
dc.format.extent9 páginas
dc.fuente.origenORCID
dc.identifier.doi10.3332/ecancer.2023.1636
dc.identifier.issn1754-6605
dc.identifier.urihttp://dx.doi.org/10.3332/ecancer.2023.1636
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/84754
dc.identifier.wosidWOS:001110515500001
dc.information.autorucEscuela de Medicina; Acevedo Claros, Francisco Nicolas; 0000-0003-3482-7746; 119540
dc.information.autorucEscuela de Medicina; Walbaum García, Benjamín Vicente; 0000-0003-2314-5360; 163702
dc.information.autorucEscuela de Medicina; Muñiz Muñoz, María Sabrina; S/I; 1023831
dc.information.autorucEscuela de Enfermería; Medina Araya, Lidia Marjorie; S/I; 18566
dc.information.autorucEscuela de Medicina; Ibáñez Cáceres, Carolina; S/I; 146063
dc.information.autorucEscuela de Medicina; Merino Lara, Tomás Rodrigo; 0000-0003-3661-9123; 119017
dc.information.autorucEscuela de Medicina; Acevedo Claros, Francisco Nicolás; 0000-0003-3482-7746; 119540
dc.information.autorucEscuela de Medicina; Bennett Laso, José Tomás; S/I; 195686
dc.information.autorucEscuela de Medicina; Sánchez Rojel, César Giovanni; 0000-0002-2920-108X; 135644
dc.language.isoen
dc.nota.accesocontenido completo
dc.pagina.final9
dc.pagina.inicio1
dc.revistaEcancer medical science
dc.rightsacceso abierto
dc.subjectAdvanced breast cancer
dc.subjectHormone receptor-positive
dc.subjectCDK4/6 inhibitors
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePalbociclib in advanced stage hormone receptor-positive breast cancer: real- world data from a Chilean multicentre registry
dc.typeartículo
dc.volumen17
sipa.codpersvinculados119540
sipa.codpersvinculados163702
sipa.codpersvinculados1023831
sipa.codpersvinculados18566
sipa.codpersvinculados146063
sipa.codpersvinculados119017
sipa.codpersvinculados195686
sipa.codpersvinculados135644
sipa.trazabilidadORCID;2024-03-25
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ecancermedicalscience-2023-article-1636.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas